All Healthcare is not Local: The Human Cost of Disparate Health Data

Food Insecurity and the Dangers of Infant Formula Dilution

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

January 30th 2023

Caffeine proposed as a potential tool in reducing risk of SIDS

Demystifying Infant Formula

Caffeine may protect infants from SIDS by reducing oxygen drops, offering a potential new tool alongside safe sleep practices, a recent study suggests.

October 11th 2022

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Michael O. Daines, MD

John Browning, MD, explains dermatological questions to ask, answer in primary care

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

John Browning, MD

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent non-steroidals, and what questions to ask patients in office.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

January 30th 2023

Caffeine proposed as a potential tool in reducing risk of SIDS

Demystifying Infant Formula

Caffeine may protect infants from SIDS by reducing oxygen drops, offering a potential new tool alongside safe sleep practices, a recent study suggests.

October 11th 2022

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Michael O. Daines, MD

John Browning, MD, explains dermatological questions to ask, answer in primary care

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

John Browning, MD